Crohn-betegség: vizsgálatok itt: Kína
73 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- No phaseNot yet taking people in KínaEfficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 185
- Run by
- Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07344428 - No phaseTaking peopleComparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
- Where
- Shanghai
- Életkor
- 18 év to 85 év
- People
- 198
- Run by
- Shanghai 10th People's Hospital
See details and how to joinNCT07694674 - No phaseTaking peopleSurgery vs Biologics for Treating Stricturing CD--a RCT
- Where
- Nanjing
- Életkor
- 18 év to 60 év
- People
- 138
- Run by
- Zhu Weiming
See details and how to joinNCT05421455 - No phaseTaking peopleReal-World Study of IL-23 Inhibitors in Active Crohn's Disease
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 665
- Run by
- Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07545317 - No phaseTaking peopleIBD Biomarker Discovery and Validation Platform
- Where
- Guangzhou
- Életkor
- 14 év and over
- People
- 6000
- Run by
- Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07686406 - 2. fázisNot yet taking people in KínaA Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
- Where
- Beijing, Bengbu, Changsha, Chongqing, Fujian, Guangzhou, Hefei, Huizhou, Jiujiang, Shaoguan, Shenyang, Shenzhen, Shiyan, Wuhan, Zhengzhou, Zhuzhou
- Életkor
- 18 év to 75 év
- People
- 156 worldwide
- Run by
- Jiangsu Carephar Pharmaceutical Co., Ltd.
See details and how to joinNCT07677514 - 4. fázisTaking peopleTNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response
- Where
- Guangzhou
- Életkor
- 18 év to 65 év
- People
- 312
- Run by
- Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07510191 - 2. fázisTaking peopleA Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Where
- Chongqing, Guangdong, Guangzhou, Shanghai
- Életkor
- 18 év to 75 év
- People
- 192 worldwide
- Run by
- Takeda
See details and how to joinNCT06764615 · EU 2024-518914-18-00 - 1. fázisTaking peopleClinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
- Where
- Bengbu, Changchun, Changsha, Guangzhou, Harbin, Hengyang, Huizhou, Kunming, Luoyang, Luzhou, Meihekou, Nanjing, Nanyang, Shanghai, Shenyang, Taishan, Taiyuan, Taizhou, Tianjin, Ürümqi, Wuhan, Wuwei, Zhengzhou
- Életkor
- 18 év to 75 év
- People
- 135
- Run by
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
See details and how to joinNCT06754891 - 3. fázisTaking peopleA Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Where
- Beijing, Changsha, Hangzhou, Shanghai, Zhengzhou
- Életkor
- 2 év to 17 év
- People
- 240 worldwide
- Run by
- Takeda
See details and how to joinNCT05442567 · EU 2023-509046-36-00 - 3. fázisNot yet taking people in KínaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Where
- Beijing, Hangzhou, Shanghai, Zhengzhou
- Életkor
- 2 év to 17 év
- People
- 120 worldwide
- Run by
- Takeda
See details and how to joinNCT04779320 · EU 2023-509045-13-00 - 4. fázisTaking peopleInterleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety
- Where
- Guangzhou
- Életkor
- 18 év to 65 év
- People
- 200
- Run by
- Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07216014 - 1/2. fázisNot yet taking people in KínaBCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)
- Where
- Zhongshan
- Életkor
- 18 év to 70 év
- People
- 18
- Run by
- iCell Gene Therapeutics
See details and how to joinNCT07544160 - No phaseTaking peopleClinical Value of Intestinal Ultrasound in Predicting Clinical Relapse in Crohn's Disease Patients in Deep Remission: a Multicenter Prospective Observational Study
- Where
- Guangzhou
- Életkor
- 18 év to 70 év
- People
- 420
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07539727 - No phaseNot yet taking people in KínaAn Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 88
- Run by
- Shanghai 10th People's Hospital
See details and how to joinNCT07528040 - No phaseTaking peopleAcupuncture Reduces Relapse in Patients With Crohn's Disease: a Superiority Trial
- Where
- Shanghai
- Életkor
- 16 év to 75 év
- People
- 106
- Run by
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
See details and how to joinNCT06553053 - No phaseTaking peopleA Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07487480 - 4. fázisTaking peopleCombined Immunosuppression for Pediatric Crohn's Disease
- Where
- Shanghai
- Életkor
- 6 év to 18 év
- People
- 128
- Run by
- Children's Hospital of Fudan University
See details and how to joinNCT05043870 - No phaseTaking peopleGuselkumab Vs Ustekinumab in Stricturing Crohn's Disease
- Where
- Hangzhou
- Életkor
- 18 év to 80 év
- People
- 100
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07444060 - No phaseTaking peopleEfficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
- Where
- Beijing, Chongqing, Guangzhou, Hangzhou, Huai'an, Suzhou, Yangzhou
- Életkor
- 18 év to 65 év
- People
- 239
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT05387031 - 4. fázisTaking peopleEfficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease
- Where
- Guangzhou
- Életkor
- 18 év to 70 év
- People
- 214
- Run by
- Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT06520397 - No phaseNot yet taking people in KínaThe Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children
- Where
- Hangzhou, Jinhua, Kunming, Wenzhou
- Életkor
- 6 év to 18 év
- People
- 154
- Run by
- The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07424040 - No phaseTaking peopleProphylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD
- Where
- Hangzhou
- Életkor
- 14 év to 80 év
- People
- 300
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07385131 - No phaseTaking peopleSpecific Dietary Pattern for Crohn's Disease Patients Following Surgery
- Where
- Hangzhou
- Életkor
- 14 év and over
- People
- 35
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT05502965 - No phaseTaking peopleEpidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease
- Where
- Guangzhou
- Életkor
- 18 év to 65 év
- People
- 1400
- Run by
- Xiang Gao
See details and how to joinNCT07364734